SCHEMBL6028280

SCHEMBL6028280

CCOC(=O)C(OCC)n1cccc(N)c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
HSD17B10 Q99714 2/20 0.42
LMNA P02545 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MAPT P10636 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KDM4E B2RXH2 5/20 0.36
MMP8 P22894 1/20 0.35
PARP1 P09874 1/20 0.35
PIN1 Q13526 1/20 0.35
GLA P06280 1/20 0.35
GAA P10253 1/20 0.35
HPGD P15428 1/20 0.35
ADORA2A P29274 1/20 0.34
ADORA1 P30542 1/20 0.34
ELANE P08246 1/20 0.34
TSHR P16473 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
RORA P35398 1/20 0.34
NR5A1 Q13285 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14423555 0.84 CYP1A2 (0.44) ALDH1A1HSD17B10LMNASMN1; SMN2MAPT
SCHEMBL7432714 0.84 CYP1A2 (0.44) ALDH1A1HSD17B10LMNASMN1; SMN2MAPT
SCHEMBL6028721 0.79 L3MBTL1 (0.43) ALDH1A1SMN1; SMN2MAPTL3MBTL1KDM4E
SCHEMBL6028255 0.77 OPRK1 (0.45) HSD17B10LMNASMN1; SMN2MAPTL3MBTL1
SCHEMBL952144 0.72 PTGS2 (0.40) HSD17B10MAPTL3MBTL1KDM4EPARP1
SCHEMBL27546454 0.72 ELANE (0.39) ALDH1A1HSD17B10MAPTKDM4EHPGD
SCHEMBL952143 0.72 ELANE (0.39) ALDH1A1HSD17B10MAPTKDM4EHPGD
SCHEMBL27654221 0.72 PTGS2 (0.40) HSD17B10MAPTL3MBTL1KDM4EPARP1
SCHEMBL15799335 0.72 ELANE (0.35) ALDH1A1HSD17B10MAPTKDM4EELANE
SCHEMBL6027957 0.71 F2 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1706396-A1 N-(4-CARBAMIMIDOYL-BENZYL)-2-ALKOXY-2-HETEROCYCLYL ACETAMIDES AS INHIBITORS OF THE FORMATION OF COAGULATION FACTORS XA, IXA AND THROMBIN INDUCED BY FACTOR VIIA F.HOFFMANN-LA ROCHE AG (CH) 2006-10-04 EP disclosed
US-7056932-B2 Heterocyclyl substituted 1-alkoxy acetic acid amides HOFFMAN-LA ROCHE INC. (US) 2006-06-06 US disclosed
WO-2005058868-A1 N-(4-CARBAMIMIDOYL-BENZYL) -2-ALKOXY-2-HETEROCYCLYL ACETAMIDES AS INHIBITORS OF THE FORMATION OF COAGULATION FACTORS XA, IXA AND THROMBIN INDUCED BY FACTOR VIIA F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed
US-20050137168-A1 Heterocyclyl substituted 1-alkoxy acetic acid amides HOFFMANN-LA ROCHE INC. 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137168-A1 Heterocyclyl substituted 1-alkoxy acetic acid amides F12, TFPI, F11 ALDH1A1 89/4885HSD17B10 936/4885LMNA 2335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.